NASDAQ · Biotechnology
OCUL (OCUL) Stock
$8.50
-1.62%
NASDAQ: OCUL
Healthcare
Valuation
Financials & Margins
Annual Financials (USD)
Balance Sheet (USD)
Latest News
Ocular Therapeutix Eyes Q4 AXPAXLI NDA After FDA Alignment
MarketBeat · Jul 23, 2026
3 Cash-Burning Stocks with Open Questions
StockStory · Jul 21, 2026
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire · Jul 9, 2026
3 Small-Cap Stocks with Open Questions
StockStory · Jul 8, 2026
Ocular Therapeutix™ to Participate in July Scientific and Investor Conferences
GlobeNewswire · Jul 1, 2026
Cash Flow (USD)
Valuation & Return Ratios
Ownership
Insiders Held0.94%
Institutions Held95.81%
Institutions Float Held96.71%
Peer Comparison
About OCUL
OCUL stock trades at $8.50 with a market capitalization of $1.86B. The stock is valued at a price-to-earnings (P/E) ratio of -5.99, price-to-book of 3.02, price-to-sales of 38.54. Over the past 52 weeks the stock has ranged between $6.23 and $16.44, and currently trades 48.3% below its 52-week high.
On profitability, OCUL generates a return on equity (ROE) of -68.55%, return on capital employed of -41.28%, an operating margin of -8.65%, a net profit margin of -5.58%.